

Special Issue

Biologics for Bone and Soft Tissue Regeneration: What Is New, What Is True

Message from the Guest Editors

Injuries to the musculoskeletal system involve bone, ligaments, muscles, and tendons, producing pain, loss of function, instability, and, in the long term, osteoarthritis. Traditionally, the management of these injuries involves activity modification, physical therapy, a variety of surgical procedures, and pharmacological agents, including non-steroidal anti-inflammatory drugs, corticosteroids viscosupplementation, and narcotics. All these modalities have limitations and potential side effects. This collection highlights the current status, challenges, and emerging trends on the use of these biologic therapies for regenerating musculoskeletal tissues, including bone and soft tissues. We welcome both basic and translational original research, and review articles covering, but not limited to:

- mechanisms of action of therapeutic effects of these biologics
- therapeutics effects of these biologics in regenerating bone and/or soft tissue(s)
- comparison of these biologics to current standard treatments
- identifying research gaps to guide future research and streamline translation to clinical utilization

Guest Editors

Dr. Ashim Gupta

1. Future Biologics, Lawrenceville, GA, USA
2. South Texas Orthopaedic Research Institute (STORI Inc.), Laredo, TX, USA

Prof. Dr. Nicola Maffulli

1. Department of Trauma and Orthopaedics, Sapienza University, Roma, Italy
2. Barts and The London School of Medicine and Dentistry, Mile End Hospital, Queen Mary University of London, 275 Bancroft Road, London E1 4DG, UK
3. School of Pharmacy and Bioengineering, Keele University Faculty of Medicine, Thornburrow Drive, Stoke on Trent ST4 7QB, UK

Deadline for manuscript submissions

closed (31 July 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/119339

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).